Sep 11, 2026, 4:42 AM1 views

Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency - Slideshow

2026-09-10. The following slide deck was published by Beam Therapeutics Inc.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Seekingalpha Verified Source

Reported by SA Transcripts · Syndicated via official news feed

Read Full Story on Seekingalpha

Explore all Markets stories

Syndicated feed content with full publisher credit.

Markets Desk

More in Markets

Continue reading verified coverage and related developments on this desk.

View All

MARKETS16M AGO

Gold Falls as Traders Raise Fed Hike Bets After US Price Report

Gold fell as the latest US inflation report and surging crude prices reinforced bets that the Federal Reserve will raise interest rates this month.

MARKETS21M AGO

Nexstar Media Group, Inc. (NXST) Presents at Goldman Sachs Communacopia + Technology Conference 2026 Transcript

Nexstar Media Group, Inc. (NXST) Goldman Sachs Communacopia + Technology Conference 2026 September 10, 2026 4:45 PM EDTCompany.

MARKETS21M AGO

Gold falls below $4,350 as rising oil prices, US PPI reinforces Fed hike bets - FXStreet

Gold falls below $4,350 as rising oil prices, US PPI reinforces Fed hike bets FXStreet

MARKETS29M AGO

Oil Pushes Further Above $100 as Middle East Conflict Deepens

Oil extended its powerful rally above $100 a barrel following an escalation of hostilities in the Middle East that has stoked fears of deeper supply disruptions.

MARKETS31M AGO

IBEX Limited (IBEX) Q4 2026 Earnings Call Transcript

IBEX Limited (IBEX) Q4 2026 Earnings Call September 10, 2026 4:30 PM EDTCompany ParticipantsGreg Bradbury - Executive Officer.